CHA News

FDA Authorizes Booster Doses for Moderna, Johnson & Johnson COVID-19 Vaccines 

For CEOs, CMOs, CNOs, COOs, and infection prevention, quality & patient safety, employee safety staff

The Food and Drug Administration (FDA) has amended emergency use authorization (EUA) for COVID-19 vaccines to allow booster doses for the Moderna and Johnson & Johnson vaccines. Specifically, the EUA allows for a single-dose booster in the following circumstances: 

  • The use of a single booster dose of the Moderna COVID-19 vaccine may be administered at least six months after completion of the primary series to individuals: 
    • Ages 65 and older
    • Ages 18-64 at high risk of severe COVID-19 
    • Ages 18-64 with frequent institutional or occupational exposure to SARS-CoV-2 
  • The use of a single booster dose of the Johnson & Johnson COVID-19 vaccine may be administered at least two months after completion of the single-dose primary regimen to individuals ages 18 older. 

The FDA also authorizes a heterologous (or “mix and match”) booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine.